

MediReport

Behavioral Health Clinical Outcomes

Q3 2021 – Q2 2022

Over a 1-year period (Q3 2021 to Q2 2022), MediTelecare clinicians evaluated and treated **over 25,000** patients in over **400** skilled and assisted living facilities.

From this patient population, MediTelecare was able to make positive improvement in key clinical outcomes as identified by CMS and MediTelecare facility partners.

Reduction in Antipsychotic Use



80% of facilities using MediTelecare's services saw a reduction in overall antipsychotic use for those patients treated by MediTelecare.



Antipsychotic use is a key measurement in the CMS quality measures that determine facility star ratings, signifying quality of patient care.

Reduction in Falls



45% of facilities using MediTelecare's services saw a reduction in patients experiencing a fall while on an antipsychotic medication.



Falls are associated with negative patient outcomes such as major injury and hospitalization. High risk psychotropic medications such as antipsychotics increase fall risk.

MediReport

Behavioral Health Clinical Outcomes

Q3 2021 – Q2 2022

Reduction in Depressive Symptoms



From Q3 2021 to Q2 2022, MediTelecare assessed a subset study population of 509 patients with moderate to severe depressive symptoms.

- Patients were assessed for depressive symptom severity using the *Patient Health Questionnaire-9 (PHQ-9)*, a widely accepted screening and evaluation assessment for depression.
- In Q3 2021, patients had a score of 10 to 27, signifying moderate to severe depressive symptoms ranging from feelings of hopelessness to suicidal thoughts.
- Throughout the treatment period from Q3 2021 to Q2 2022, patients were re-assessed at least once more using the PHQ-9.



84% of patients with moderate to severe symptom severity showed symptom improvement

- 428 out of 509 with moderate to severe depressive symptoms had a reduction in symptom severity on their repeat PHQ-9 assessment.
- Average reduction in PHQ-9 scores was 7 points with 80% having no/minimal to mild symptom severity on repeat assessment.



94% of patients with the highest scores classifying as moderately severe to severe symptom severity showed symptom improvement

- 126 out of 134 with moderately severe to severe depressive symptom severity as defined by scores of 15-27 had a reduction in depressive symptom severity.
- Average reduction in PHQ-9 scores was 10 points with 64% having no/minimal to mild symptom severity on repeat assessment.